Item 8.01 Other Events.

Propanc Biopharma Inc. (the "Company") has retired its final convertible promissory note, dated June 30, 2022 (the "Note"), in favor of 1800 Diagonal Lending LLC (the "Holder"). The Note was previously disclosed in the Company's Current Report on Form 8-K filed on July 7, 2022.

On February 15, 2023, the Company initiated and made full and final payment of the Note, fully converting all outstanding principal and interest into shares of the Company's common stock, leaving a zero balance remaining. Accordingly, the parties have no further rights or obligations as to each other as to the debt that had been memorialized by the Note, and the Company does not have any remaining obligations to issue any of its securities to the Holder.

Note: the information in this Current Report (including any exhibits) shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. This Current Report will not be deemed a determination or an admission as to the materiality of any information in the report that is required to be disclosed solely by Regulation FD.

© Edgar Online, source Glimpses